Prevention Of Asthma In Young Children Via Immunostimulation
Funder
National Health and Medical Research Council
Funding Amount
$679,683.00
Summary
Persistent asthma is a major problem for Australia yet none of the current therapies do more that control the condition. The long-term solution is to prevent asthma from progressing to the persistent form. The major risk factors are: family history, early allergy and recurrent severe lower respiratory infections (sLRI) in the early life. We will conduct a randomized clinical trial to prevent sLRI using a novel bacterial-derived immunostimulant in infants at high risk of developing asthma.
Effect Of Anti-IgE Antibody On Immune System Responses And Short-term Outcome In Acute Asthma In Children
Funder
National Health and Medical Research Council
Funding Amount
$571,752.00
Summary
We plan to undertake a randomised, double-blind, placebo-controlled, clinical trial of anti-IgE antibody given at the time of an acute attack of asthma in children aged 6-12 years. The idea for this arose from our own novel data – IgE levels increase with the most common infection causing acute asthma. Given evidence the virus uses IgE to cause inflammation, giving anti-IgE during the attack should reduce the severity of the attack and produce a new, effective treatment for acute asthma.
Conquering The Final Frontier In Lung Transplantation - Mesenchymal Stromal Cell Therapy For Chronic Lung Allograft Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$1,887,790.00
Summary
Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.
Winter-only Treatment With Omalizumab To Prevent Asthma Exacerbations In Children.
Funder
National Health and Medical Research Council
Funding Amount
$738,855.00
Summary
Acute exacerbations of asthma add considerably to the economic and social burden imposed by asthma. Current asthma treatment frequently controls underlying asthma but does not prevent acute exacerbations in exacerbation-prone asthmatics. This trial, based on our asthma research, provides new hope that acute asthma can be prevented.
Testing The Lung Microbiome To Predict Risk Of Frequent Exacerbations In COPD
Funder
National Health and Medical Research Council
Funding Amount
$666,052.00
Summary
Chronic obstructive pulmonary disease (COPD) is a disease of global importance. Exacerbations, mostly due to respiratory infection, are complications that lead to significant illness. This study will characterise the communities of microbes in the lung, and use this information to predict frequency of exacerbations of COPD measured over 12 months.
The Clinical Effectiveness Of A Simple New Treatment For Supine-dependent Obstructive Sleep Apnoea
Funder
National Health and Medical Research Council
Funding Amount
$529,178.00
Summary
Obstructive sleep apnoea is a common and debilitating breathing problem in sleep with serious effects on sleep and health. A third of patients could be very simply treated by avoiding sleeping on their back. Existing treatments are uncomfortable, often not used and better options are needed. This project will test symptom relief and treatment adherence with a new comfortable low cost supine avoidance therapy against current best practice treatment.
The Sleep Apnea Cardio Vascular Endpoints (SAVE) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,177,047.00
Summary
Obstructive sleep apnea (OSA) affects 7% of the population and is increasing with the global epidemic of obesity. Research suggests that OSA may be a cause of premature cardiovascular (CV) disease, but definitive proof is lacking. This 5-year trial will answer this question by comparing the rate of CV events (eg stroke, heart attack) in OSA patients who are treated, versus those not treated, with CPAP. The results may lead to a new medical approach to the prevention of CV disease.
Obstructive sleep apnea (OSA) affects 7% of the population and is increasing with the global epidemic of obesity. Research suggests that OSA may be a cause of premature cardiovascular (CV) disease, but definitive proof is lacking. This 5-year trial will answer this question by comparing the rate of CV events (eg stroke, heart attack) in OSA patients who are treated, versus those not treated, with CPAP. The results may lead to a new medical approach to the prevention of CV disease.
Novel Interventions For The Diverse Population Of Australians With Bronchiectasis
Funder
National Health and Medical Research Council
Funding Amount
$726,822.00
Summary
Bronchiectasis is a chronic lung condition in which infection causes wheeze, breathlessness, fatigue and sputum production - markedly reducing quality of life and requiring repeated hospital admissions. Risk of hospitalisation due to the disease is up to 9-fold higher in Indigenous vs other Australians. This research will examine two new, low-cost therapies with excellent potential to treat bronchiectasis: a new antibiotic, Azithromycin, and a mucus-clearance agent, hypertonic saline.